Boston Scientific Gets Downgraded to Neutral By Citigroup

Jacob Harper |

Citigroup Inc (C) downgraded Boston Scientific Corp (BSX) to “neutral” on July 9. This follows a downgrading of the medical device maker’s stock by Credit Suisse in April and a holding of a neutral rating from Zack’s in June. Analysts are concerned that the soaring stock has overstepped its potential as it trades near its three-year high. Boston Scientific has risen dramatically in 2013 on news of the products in its pipeline.

But some analysts have asserted that the stock has already factored in these developments into its current price. Matthew Dodds asserted that future sales of these devices would merely counteract the declining sales of outdated products. This is good news for medical device competitors St. Jude Medical, Inc. (STJ), Johnson & Johnson (JNJ)and Medtronic, Inc. (MDT).



Boston Scientific started their surge in 2013 following promising trials of the Watchman Left Atrial Appendage (LAA) closure device, used to treat irregular heartbeats. The device has been approved in Europe since 2005. Investors were further impressed with a four percent growth in their medical surgery, or MedSurg, division.

Emboldened by their recent success, Boston Scientific finalized a deal to buy electrophysiology company Bard EP for $275 million cash in April. This follows years of decline for Boston Scientific. In 2006 they spent $27.2 billion cash to buy Guidant, outbidding Johnson & Johnson. The deal ended up costing Boston Scientific dearly, as costy product recalls irreversibly damaged Boston Scientific’s stock. Prior to the Guidant buyout, Boston Scientific traded north of $40 a share.

Boston Scientific is down .22 percent to $9.28 a share. The Natick, Mass. company is up 61.78 percent on the year.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
JNJ Johnson & Johnson 142.40 0.36 0.25 5,581,804 Trade
C Citigroup Inc. 73.53 0.65 0.89 15,511,479 Trade
BSX Boston Scientific Corporation 29.69 0.12 0.41 4,687,586 Trade
MDT Medtronic plc. 78.34 -0.14 -0.18 4,130,512 Trade
STJ St. Jude Medical Inc. n/a n/a n/a 0 Trade
GTXO GTX Corp 0.00 -0.00 -14.29 1,945,400

Comments

Emerging Growth

Viking Energy Group Inc

Viking Investments Group Inc provides professional advisory and consulting services to companies undergoing or anticipating periods of rapid growth, change or ownership transition.

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…